InsidersTradesSigma
STRATA Skin Sciences, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the STRATA Skin Sciences, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, STRATA Skin Sciences, Inc. has published 32 reports. Market capitalisation: €7.4m. The latest transaction was disclosed on 17 July 2024 (Acquisition). Among the most active insiders: Rubinstein Samuel. Every trade is openly available.
32
Insider Decl.
0
Thresholds
€2m
14 ops.
Buy Volume
€295
1 ops.
Sell Volume
60Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 July 2024
Declarations32 total
19,100 shares@ US$3.14100.0% of flowCommon StockSEC:0001051514-24-000005:0
Ideal exit: 11 Apr 2025 (T+270)
230,573 shares@ US$3.14100.0% of flowCommon StockSEC:0001213900-24-062198:0
Ideal exit: 11 Apr 2025 (T+270)
230,573 shares@ US$3.14100.0% of flowCommon StockSEC:0001213900-24-062197:0
Ideal exit: 11 Apr 2025 (T+270)
14,338 shares@ US$0.44100.0% of flowSSKN Common StockSEC:0001051514-23-000070:0
Ideal exit: 27 Aug 2024 (T+270)
1,000 shares@ US$0.320.4% of flowCommon StockSEC:0001051514-23-000064:0
42,000 shares@ US$0.67435.1% of flowSSKN Common StockSEC:0001051514-23-000036:0
Ideal exit: 6 May 2024 (T+270)
5,151 shares@ US$0.6811.3% of flowSSKN Common StockSEC:0001051514-23-000038:0
Ideal exit: 6 May 2024 (T+270)
36,408 shares@ US$1.0341.9% of flowSSKN Common StockSEC:0001051514-23-000029:0
38,835 shares@ US$1.0347.4% of flowSSKN Common StockSEC:0001051514-23-000030:0
33,981 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000032:0
36,408 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000031:0
33,981 shares@ US$1.0348.1% of flowSSKN Common StockSEC:0001051514-23-000028:0
37,838 shares@ US$0.92549.9% of flowSSKN Common StockSEC:0001051514-22-000075:0
9,106 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000074:0
43,244 shares@ US$0.92549.1% of flowSSKN Common StockSEC:0001051514-22-000076:0
9,756 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000073:0
1,050 shares@ US$1.040.014% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000065:0
Ideal exit: 12 Mar 2023 (T+270)
23,131 shares@ US$1.120.34% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000057:0
Ideal exit: 6 Feb 2023 (T+270)
16,950 shares@ US$1.73360.36% mcap55.7% of flowSSKN Common StockSEC:0001051514-22-000035:0
Ideal exit: 20 Dec 2022 (T+270)
14,783 shares@ US$1.5820.29% mcap44.3% of flowSSKN Common StockSEC:0001051514-22-000033:0
Ideal exit: 19 Dec 2022 (T+270)
33,300 shares@ US$1.57350.64% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000032:0
Ideal exit: 19 Dec 2022 (T+270)
1,155 shares@ US$1.40100.0% of flowSSKN Common StockSEC:0001051514-21-000064
Ideal exit: 4 Jun 2022 (T+270)
1,155 shares@ US$1.400.018% mcap50.0% of flowSSKN Common StockSEC:0001051514-21-000064:0
Ideal exit: 4 Jun 2022 (T+270)
20,000 shares0SSKN Common StockSEC:0001051514-21-000034
25 of 32 declarations
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc. is a U.S. medical technology company focused on dermatology and listed on the NASDAQ market in the United States. Headquartered in Horsham, Pennsylvania, the company serves dermatologists and their patients with targeted treatment platforms for chronic skin conditions. Its profile is that of a niche med-tech player rather than a broad pharmaceutical company, with a business model that combines equipment sales and recurring revenue from utilization of its installed base. The company has evolved around excimer laser technology and later sharpened its focus through portfolio reshaping and acquisitions. STRATA moved away from its former MelaFind initiative and changed its name in 2016. Today, its core commercial offerings include the XTRAC® and Pharos® excimer lasers and the VTRAC® lamp system, which are used in the treatment of psoriasis, vitiligo, and other inflammatory or autoimmune dermatologic disorders. In 2022, STRATA broadened its strategy with the acquisition of the TheraClear® Acne Therapy System, marketed as TheraClear® X, giving the company exposure to the acne treatment market as well. From a competitive standpoint, STRATA differentiates itself through highly targeted UVB-light treatment technologies aimed at large but often under-served dermatology indications. The company reports an installed base of systems in dermatology offices, primarily in the United States, alongside a smaller but growing international footprint. Its economics are driven by recurring procedure revenue, which can provide more stability than an equipment-only model. Recent developments suggest a company still in an operational rebuilding and expansion phase. In 2025, STRATA reported modest quarterly revenue growth, continued international momentum, and progress on expanding CPT reimbursement codes for inflammatory and autoimmune skin diseases in the United States, potentially increasing the addressable market. The company also obtained Mexican regulatory clearance for TheraClearX and began first commercial placements there. At the same time, recent SEC filings show that the common stock was delisted from the Nasdaq Capital Market as of February 19, 2026 and is now quoted over the counter (OTC), which is a material consideration for investors assessing liquidity and financing risk. For French, Belgian, and Swiss investors, STRATA is therefore a U.S. healthcare small cap with exposure to both clinical adoption and reimbursement expansion. The equity should be viewed as a higher-risk, higher-volatility med-tech name, with progress dependent on commercialization execution, payer coverage expansion, and balance-sheet support.
